

1 **Assessment of oxidative stress markers in elderly patients with SARS-CoV-2 infection and potential**
2 **prognostic implications. An observational study**

3

4 **Oxidative stress markers in elderly patients with SARS-CoV-2 infection**

5

6 Nestor Vazquez-Agra^{1*}, Ana-Teresa Marques-Afonso¹, Anton Cruces-Sande^{2*}, Ignacio Novo-Veleiro¹, Antonio
7 Pose-Reino¹, Estefania Mendez-Alvarez², Ramon Soto-Otero², Alvaro Hermida-Ameijeiras¹

8

9 ¹ Department of Internal Medicine. University Hospital of Santiago de Compostela, 15706, A Choupana Street, A
10 Coruña, Spain;

11 ² Laboratory of neurochemistry. Department of Biochemistry and Molecular Biology. Faculty of Medicine.
12 University of Santiago de Compostela, 15782, San Francisco Street, A Coruña, Spain;

13

14 *Corresponding authors

15

16 Nestor Vazquez-Agra. E-mail: Nestor.Vazquez.Agra@sergas.es. Department of Internal Medicine. University
17 Hospital of Santiago de Compostela, 15706, A Choupana Street, A Coruña, Spain. Anton Cruces-Sande. E-mail:
18 anton.cruces@usc.es. Laboratory of neurochemistry. Department of Biochemistry and Molecular Biology. Faculty
19 of Medicine. University of Santiago de Compostela, 15782, San Francisco Street, A Coruña, Spain;

20

21 **Author contributions:**

22

23 Conceptualization – Nestor Vazquez-Agra, Anton Cruces-Sande, Alvaro Hermida-Ameijeiras. Data curation and
24 formal analysis – Ana-Teresa Marques-Afonso, Ignacio Novo-Veleiro, Nestor Vazquez-Agra. Investigation and
25 methodology – Nestor Vazquez-Agra, Anton Cruces-Sande. Supervision and validation: Estefania Mendez-Alvarez,
26 Ramon Soto-Otero, Antonio Pose-Reino, Alvaro Hermida-Ameijeiras. Writing (Original Draft Preparation) – Nestor
27 Vazquez-Agra. Writing (Review & Editing): Nestor Vazquez-Agra. Final approval of the version to be published –
28 All authors.

29

30

31 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

32

33

34

35

36 **Abstract**

37

38 The aim of the study was to evaluate the correlation of plasma levels of thiobarbituric acid reactive substances
39 (TBARS) and reduced thiols with morbidity, mortality and immune response in SARS-CoV-2 infection. This was an
40 observational study that included inpatients with SARS-CoV-2 infection greater than 65 years old. Individuals were
41 followed up until 12 months after hospital discharge. Demographic, clinical and laboratory variables were collected.
42 Plasma levels of TBARS and reduced thiols were quantified as a measure of lipid and protein oxidation,
43 respectively. Events of interest (fatal and non-fatal) were quantified at hospital discharge, third, sixth and twelfth-
44 month post-discharge. The outcomes were differences in oxidative stress markers between groups of interest and
45 time to a negative RT-qPCR and to significant anti-SARS-CoV-2 IgM titers. There were 61 patients (57% women)
46 with a mean age of 83 years old. Patients with higher levels of TBARS and lower levels of reduced thiols had more
47 risk of fatal and non-fatal events between admission and the first 12 months post-discharge. The presence of any
48 event (fatal or non-fatal) at the end of the first 12 months post-discharge was correlated with TBARS levels, anti-
49 SARS-CoV-2 IgM titers, lactate dehydrogenase, platelet count and neutrophil and lymphocyte count. We found a
50 correlation between plasma reduced thiols and time to achieve significant anti-SARS-CoV-2 IgM titers. Assessment
51 of some parameters related to oxidative stress could help to identify groups of patients with a higher risk of
52 morbidity and mortality during and after SARS-CoV-2 infection.

53

54

55 **Keywords**

56 Oxidative stress; thiobarbituric acid reactive substances; lipid peroxidation; thiol; SARS-CoV-2; prognostic;

57

58

59

60

61 **Introduction**

62

63 The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was identified as the cause of a cluster of
64 pneumonia cases in Wuhan (China) at the end of 2019. Symptoms appear in six out of ten patients and about 15% of
65 individuals suffer from severe disease defined as appearance of dyspnea, hypoxemia and major lung involvement on
66 imaging tests [1, 2].

67

68 Multiple studies support the existence of a dual interaction between inflammation and oxidative stress which could
69 leads to an unfavorable inflammatory status that would be related to organ damage and poor prognosis in several
70 acute and chronic diseases [3, 4].

71

72 In this line, literature suggests that an exacerbated inflammatory response in predisposed individuals could be one of
73 the main causes of prognostic differences between patients with SARS-CoV-2 infection. Indeed, patients with
74 elevated inflammatory markers such as C-reactive protein (CRP), ferritin, fibrinogen and some pro-inflammatory
75 cytokines, such as interleukin 6 (IL-6) and tumor necrosis factor alpha (TNF- α) are at increased risk of severe
76 complications [5, 6].

77

78 However, the role of redox imbalance in the prognosis of SARS-CoV-2 infection in the short and even medium to
79 long term remains poorly understood since most of research on SARS-CoV-2 and oxidative stress are reviews of
80 clinical, translational and basic studies related to SARS-CoV-2 virulence and pathogenicity or to several diseases that
81 could share some pathogenic mechanisms [7, 8].

82

83 The instability and high reactivity of reactive oxygen species (ROS) implies the need for quantification of secondary
84 but more stable organic products derived from their oxidative action. Some of the most quantified oxidative stress
85 markers in literature are thiobarbituric acid reactive substances (TBARS) and reduced thiols as a measure of lipid
86 and protein oxidation, respectively. The assessment of TBARS and reduced thiols as a prognostic tool is widely
87 supported in some diseases and it would not be negligible that they could also provide prognostic information in
88 SARS-CoV-2 infection [9-11].

89

90 Thus, the aim of our study was to quantify plasma TBARS and reduced thiol levels in patients with SARS-CoV-2
91 infection and to assess whether there is a correlation between these oxidative stress markers and some prognostic
92 variables related to morbidity, mortality and immunity response during and after SARS-CoV-2 infection.

93

94 **Material and Methods**

95

96 **Study design and framework**

97

98 This was an observational study conducted in a SARS-CoV-2 inpatient unit belonging to the Department of Internal
99 Medicine of the University Hospital of Santiago de Compostela (Galicia, Spain) from November/2020 to
100 January/2021. Patients were recruited at hospital admission and followed up until twelve months after hospital
101 discharge. The events of interest were quantified at hospital discharge, third, sixth and twelfth-month of follow-up.

102

103 **Participants**

104

105 We identified patients older than 65 years old with confirmed SARS-CoV-2 infection by microbiological criteria
106 who met admission criteria (presence of risk factors or severe disease characterized as the appearance of dyspnea,
107 hypoxemia [O₂ saturation lower than 94%] or pulmonary involvement greater than 50%). Patients were randomly
108 selected from the complete cohort of patients admitted to hospital with SARS-CoV-2 infection. Individuals with a
109 Barthel index lower than 35 points and those without a record of a laboratory test within the first seven days of
110 admission were excluded [12].

111

112 **Clinical variables**

113

114 All patients were assessed for demographic characteristics (age and sex), cardiovascular (CV) risk factors including
115 smoking status (non-smokers versus current or former smokers), alcohol intake (no consumption versus
116 consumption of any amount), body weight (normal weight versus obesity according to body mass index [BMI]),

117 diabetes mellitus (DM), hyperlipidemia (HLP) and arterial hypertension (AHT). AHT and HLP were defined
118 according to ESC Clinical Practice Guidelines [13, 14]. DM was considered according to American Diabetes
119 Association guidelines (ADA) [15].

120

121 Patients were also investigated for the presence of chronic CV disease (coronary arterial and cerebrovascular
122 disease, hearth failure [HF] and atrial fibrillation [AF]), acute or chronic renal impairment and chronic respiratory
123 diseases including chronic pulmonary obstructive disease (COPD), obesity-hypoventilation syndrome and sleep-
124 apnea syndrome. Definitions were taken into account in accordance with the corresponding clinical guidelines [16-
125 18].

126

127 The presence of cognitive impairment was confirmed with data collected from the patient's clinical history and in
128 those cases without previous information we performed the Pfeiffer test [19]. Barthel index punctuation equal or
129 lower than 55 points was considered as moderate physical dependence.

130

131 We considered as drug-related variables chronic treatment with anticoagulant, antiplatelet and systemic steroid
132 agents, as well as acute management with antibiotics (azithromycin or others such as B-lactams), systemic steroids
133 and need for supplemental oxygen therapy.

134

135 **Laboratory variables**

136

137 All patients underwent a blood test between days 5 and 7 of hospital admission. Blood samples were obtained at
138 08:00 AM following overnight fasting. The collected analytical parameters were complete blood count including
139 hemoglobin (Hb), platelet count (PTC) and white blood cell (WBC) count, biochemistry parameters including serum
140 glucose, creatinine, urea and triglycerides (TG), and those related to coagulation. As inflammatory markers they
141 were included the ultrasensitive C-reactive protein (US-CRP), procalcitonin, IL-6, lactate dehydrogenase (LDH),
142 fibrinogen and ferritin [20-22].

143

144 Sample collection for the diagnosis of SARS-CoV-2 was performed in the upper respiratory tract in all patients.

145 Detection of SARS-CoV-2 was carried out by using the real-time reverse transcriptase-polymerase chain reaction
146 (RT-qPCR) and results were qualitatively reported as negative, positive or indeterminate. The detection of anti-

147 SARS-CoV-2 IgM antibodies was performed by enzyme-linked immunosorbent assay (ELISA) and results were
148 provided quantitatively [23, 24].

149

150 **Assessment of oxidative stress markers**

151

152 Blood samples were collected in tubes with EDTA, centrifuged in less than 1 hour after extraction at 1000 G and
153 4°C for 10 minutes with extraction of the plasma fraction and deposited at -80°C for less than 1 month until analysis
154 [25].

155

156 TBARS measurement is a well-established method for screening and monitoring lipid peroxidation. There are
157 multiple lipid peroxidation products of which the most relevant and quantified is malondialdehyde (MDA). The
158 MDA-Thiobarbituric acid (TBA) adducts formed by the reaction of MDA and TBA under high temperature (90-100
159 °C) and acidic conditions were spectrophotometrically measured at 530-540 nm. Assessment of lipid peroxidation
160 was carried out following the protocol of Ohkawa et al [26]. Absorbance was directly proportional to the level of
161 lipid peroxides in plasma and TBARS concentration (expressed in terms of MDA) was given in micromolar
162 ($\mu\text{mol/L}$). According to literature, physiological concentrations of plasma TBARS range between 0.26 and 3.94
163 $\mu\text{mol/L}$ [27].

164

165 Assessment of reduced thiols is a well-systematized technique for quantification of protein oxidation. Ellman's
166 technique uses 5,5-dithio-bis-(2-nitrobenzoic acid) as a reagent to form a compound with the sulfhydryl groups of
167 some amino acid residues in proteins giving rise to a colorful pigment that absorbs a wavelength of 412 nm and
168 whose absorbance is proportional to the level of reduced thiols in plasma proteins. Reduced thiols levels were given
169 in millimolar (mmol/L). According to literature, physiological concentrations of plasma reduced thiols range
170 between 0.4 and 0.6 mmol/L [10, 28].

171

172 All samples were analyzed in duplicate and a standard calibration for each protocol was performed obtaining a
173 linear model with a coefficient of determination (R^2) greater than 98%.

174

175 **Outcomes**

176

177 Mortality was defined as a fatal event. We grouped it into four main categories as follows: I) In-hospital fatal events;
178 II) 3^o-month post-discharge fatal events; III) 6^o-month post-discharge fatal events and IV) 12^o-month post-discharge
179 fatal events.

180

181 Non-fatal events were grouped into four main categories as follows: I) In-hospital non-fatal events (which referred
182 to the need for transfer during admission to a critical respiratory care unit); II) 3^o-month post-discharge non-fatal
183 events; III) 6^o-month post-discharge non-fatal events; IV) 12^o-month post-discharge non-fatal events (which referred
184 to the need for readmission to hospital for respiratory or cardiovascular disease within 3, 6 and 12 months post-
185 discharge).

186

187 Total events were defined as presence or absence of any fatal or non-fatal events for each of the groups listed
188 previously (In-hospital, 3^o, 6^o and 12^o-month post-discharge). The other outcomes were time to significant anti-
189 SARS-CoV-2 IgM titers (considering mean titers as the threshold) and time to a negative RT-qPCR.

190

191 **Calculation of sample size and treatment of variables**

192

193 For an unknown population size, considering a variance of 0.5 and 0.05 with a threshold for the mean difference to
194 be detected of 0.5 and 0.05 units for TBARS and reduced thiols respectively, the sample size calculated to estimate
195 the mean difference between groups with a 95% confidence interval was a minimum of $n = 30$ patients [29].
196 Variables were collected according to data provided by the regional digital health records (IANUS) belonging to the
197 Galician (Spain) Health Service (SERGAS). Most of the clinical variables were coded as qualitative ones and
198 laboratory parameters including TBARS and reduce thiols were collected as continuous quantitative variables.
199 Outcome variables were coded as dichotomous qualitative variables.

200

201 **Ethical approval**

202

203 The study was approved by the Research Ethics Committee of Santiago de Compostela-Lugo (2020/578). All
204 procedures were in accordance with the ethical standards of the responsible committee on human experimentation

205 and with the Helsinki Declaration of 1975. Informed consent was obtained from all patients for being included in the
206 study.

207

208 **Statistical analysis**

209

210 Statistical analysis was performed by using SPSS 22.0 statistical software (SPSS Inc, Chicago, IL). First, we made a
211 descriptive analysis in which frequencies of qualitative variables were expressed as number (n) and percentage (%).

212 The Kolmogorov-Smirnov test was used to determine whether quantitative continuous variables were normally
213 distributed. Normally distributed variables were expressed as mean (m) and standard deviation (\pm SD) and non-
214 normally ones were expressed as median and interquartile range (IQR). A missing value analysis was carried out on
215 those variables with more than 5% of missing values.

216

217 We carried out a comparative analysis between groups of patients according to the outcome variables. The chi-
218 square test was used to compare categorical variables while quantitative variables were compared by using the
219 Student's t-test or Mann-Whitney U test where appropriate. For multivariate analysis, a binary logistic regression
220 model was developed on the relevant clinical and laboratory variables. The calculated probability was evaluated
221 with a receiver operating characteristic (ROC) curve model. Time to significant anti-SARS-CoV-2 IgM titers and
222 time to a negative RT-qPCR were used to construct a survival analysis model by using the Kaplan-Meier estimator
223 attending to the level of TBARS and reduced thiols. A P-value less than 0.05 was considered for statistical
224 significance.

225

226 **Results**

227

228 Quantitative variables were normally distributed and we only registered more than 5% of missing values in alcohol
229 intake, smoking habit (current/former smokers) and level of physical dependence (Barthel index), which were found
230 to be missing values at random. There were 61 patients (57% women) with a mean age of 83 years old who were
231 included in the study, and among them, 42 (69%), 31(51%) and 15(25%) suffered from AHT, HLP and DM
232 respectively. A total of 27(44%) and 21(34%) individuals were affected of HF and AF. Approximately one out of
233 four individuals had tobacco or alcohol abuse and most of them were former users (data not shown). The mean

234 levels of TBARS and reduced thiols were $3.11 \pm 0.09 \mu\text{mol/L}$ and $0.46 \pm 0.07 \text{ mmol/L}$ respectively. The mean
 235 levels of anti-SARS-CoV-2 IgM titers were $40 \pm 38 \text{ U/mL}$. General results are shown in Table 1 and complete
 236 clinical features are provided in S1 Table.
 237

Table 1. Clinical and laboratory features of comparison groups attending to mortality

Variables	Total sample N= 61	In-hospital fatal events		Post-discharge fatal events					
		No n= 57	Yes n= 4	3 months		6 months		12 months	
				No n= 54	Yes n= 7	No n= 52	Yes n= 9	No n= 47	Yes n= 13
Age (years)†	83±7	83±7	81±5	83±7	80±4	83±7	78±4*	83±7	81±6
Sex (women)‡	35(57)	33(58)	2(50)	31(57)	4(57)	30(58)	5(56)	27(59)	6(46)
Obesity‡	23(38)	23(41)	0(0)	23(43)	0(0)*	23(45)	0(0)*	22(49)	1(8)*
Alcohol intake‡	13(23)	12(23)	1(25)	12(24)	1(14)	11(23)	2(22)	10(24)	3(23)
Current/Former smokers‡	14(26)	13(26)	1(25)	12(25)	2(28)	11(24)	3(33)	8(20)	6(46)
AHT‡	42(69)	38(67)	4(100)	35(64)	7(100)	34(65)	8(89)	29(63)	11(85)
HLP‡	31(51)	30(52)	1(25)	28(52)	3(43)	27(52)	4(44)	23(50)	7(54)
DM‡	15(25)	15(26)	0(0)	15(27)	0(0)	13(25)	2(22)	13(28)	2(15)
HF‡	27(44)	26(41)	1(25)	23(42)	4(57)	22(42)	5(56)	18(39)	8(61)
Cognitive impairment‡	28(47)	25(45)	3(75)	24(45)	4(57)	23(45)	5(56)	22(49)	6(46)
Barthel index (≤ 55)	31(57)	29(55)	2(50)	28(57)	3(50)	27(57)	4(50)	23(56)	7(57)
FPG (mg/dL)†	115 ± 64	110 ± 53	184 ± 148	110 ± 55	153 ± 112	110 ± 55	140 ± 101	111 ± 57	130 ± 86
Creatinine (mg/dL)†	0.9 ± 0.4	0.9 ± 0.3	0.7 ± 0.1	0.9 ± 0.4	0.9 ± 0.3	0.9 ± 0.4	0.9 ± 0.3	1.0 ± 0.4	0.9 ± 0.3
Albumin (g/dL)†	3.8 ± 0.5	3.8 ± 0.5	3.6 ± 0.3	3.8 ± 0.5	3.6 ± 0.3	3.8 ± 0.5	3.7 ± 0.4	3.9 ± 0.5	3.6 ± 0.4
TG (mg/dL)†	124 ± 59	121 ± 58	141 ± 65	122 ± 57	135 ± 75	122 ± 58	132 ± 65	122 ± 58	133 ± 63
LDH (U/L)†	426 ±	417 ±	557 ±	418 ±	485 ±	421 ±	453 ±	412 ±	486 ±

	163	162	135	164	146	167	143	151	199
PTC ($10^3/\mu\text{L}$)†	207 ± 85	173 ± 86	206 ± 87	195 ± 77	207 ± 88	188 ± 70	205 ± 84	183 ± 62	207 ± 85
Neutrophils ($10^3/\mu\text{L}$) †	4.7 ± 3.2	7.1 ± 4.2	4.5 ± 3.1	6.4 ± 3.6	4.5 ± 3.2	6.0 ± 3.6	4.5 ± 3.3	5.9 ± 3.1	7.1 ± 4.2
Lymphocytes ($10^3/\mu\text{L}$) †	2.9 ± 5.8	3.1 ± 6	0.8 ± 0.5	2.7 ± 5.2	4.5 ± 9.8	2.6 ± 5.2	4.6 ± 8.6	2.6 ± 5.4	4.1 ± 7.3

AHT–Arterial hypertension. HLP–Hyperlipidemia. DM–Diabetes mellitus. HF–Heart failure. FPG–Fasting plasma glucose. TG–Triglycerides. LDH–Lactate dehydrogenase. PTC–Platelet count. Results expressed as † refer to mean ± standard deviation. Results expressed as ‡ refer to number (percentage). * Indicated comparison with patients without in-hospital, 3^o, 6^o or 12^o-month post-discharge fatal events ($P < 0.05$).

238

239 **Fatal events**

240

241 Results of the comparison groups are shown in Table 1 and extended in S1-2 Tables. In general terms, younger
 242 patients, with lower body weight and greater use of antibiotics or systemic steroids during admission presented a
 243 greater number of fatal events with statistically significant differences in the groups of 3^o, 6^o and 12^o-month post-
 244 discharge fatal events. Regarding laboratory variables, there were no relevant differences between the comparison
 245 groups.

246

247 Patients who presented a fatal event had higher TBARS levels than controls measured in $\mu\text{mol/L}$ and expressed as m
 248 ± SD. These differences reached statistical significance in the following groups: In-hospital (no: 3.02 ± 1.01 , yes:
 249 4.40 ± 1.52 ; $P = 0.014$) and 6^o-month post-discharge fatal events (no: 2.99 ± 0.98 , yes: 3.81 ± 1.44 ; $P = 0.038$). The
 250 levels of reduced thiols measured in mmol/L and expressed as m ± SD were lower in patients who suffered a fatal
 251 event. Such differences reached statistical significance in the following groups: 6^o-month (no: 0.47 ± 0.07 , yes: 0.41
 252 ± 0.05 ; $P = 0.040$) and 12^o-month (no: 0.47 ± 0.07 , yes: 0.42 ± 0.06 ; $P = 0.032$) post-discharge fatal events. The
 253 results are extended in Fig 1A and 1B.

254

255 **Fig 1. Difference between plasma levels of TBARS and reduced thiols in groups of interest**

256 (A-B) In-hospital and post-discharge fatal events. (C-D) In-hospital and post-discharge non-fatal events.

257 (E-F) In-hospital and post-discharge total events. Results are shown in mean ± standard deviation.

258 TBARS–Tiobarbituric acid reactive substances. **Refers to P -value < 0.05 .

259

260 Non-fatal events

261

262 The results of the comparison groups are shown in Table 2 and extended in S3-4 Tables. In general terms current or
 263 former smokers presented a higher number of non-fatal events with statistically significant differences in the 6^o-
 264 month and 12^o-month post-discharge non-fatal events groups. Regarding laboratory variables, we only observed
 265 relevant differences in LDH and PTC for 6^o-month and 12^o-month post-discharge non-fatal events respectively.

266

Table 2. Clinical and laboratory features of comparison groups attending to non-fatal events

Variables	In-hospital non-fatal events		Post-discharge non-fatal events					
			3 months		6 months		12 months	
	No n= 58	Yes n= 3	No n= 44	Yes n= 17	No n= 38	Yes n= 23	No n= 28	Yes n= 33
Age (years)†	82 ± 7	84 ± 6	83 ± 8	83 ± 5	83 ± 8	82 ± 6	82 ± 7	83 ± 8
Gender (women)‡	33(57)	2(67)	26(59)	9(53)	23(61)	12(52)	18(64)	17(52)
Obesity‡	23(40)	0(0)	17(40)	6(35)	15(41)	8(35)	10(36)	13(41)
Alcohol intake‡	13(25)	0(0)	8(21)	5(29)	6(18)	7(30)	4(16)	9(29)
Current/Formersmokers‡	13(25)	1(33)	8(21)	6(35)	5(16)	9(39)*	3(12)	11(37)*
AHT‡	39(67)	3(100)	27(61)	15(88)*	24(63)	18(78)	18(64)	24(73)
HLP‡	29(50)	2(67)	21(48)	10(59)	18(47)	13(57)	13(46)	18(55)
DM‡	15(26)	0(0)	10(23)	5(29)	8(21)	7(30)	6(21)	9(27)
HF‡	25(43)	2(67)	17(39)	10(59)	14(37)	13(57)	9(32)	18(55)
Cognitive impairment‡	27(47)	1(33)	21(49)	7(41)	19(51)	9(39)	14(52)	14(42)
Barthel index (≤ 55) ‡	30(57)	1(33)	21(55)	10(59)	18(56)	13(56)	17(76)	14(44)*

FPG(mg/dL)†	115 ± 65	111 ± 14	112 ± 67	122 ± 56	112 ± 71	119 ± 50	111 ± 62	117 ± 66
Creatinine (mg/dL)†	0.9 ± 0.4	0.8 ± 0.2	0.9 ± 0.3	1.0 ± 0.5	0.9 ± 0.3	0.9 ± 0.4	0.9 ± 0.3	1.0 ± 0.4
Albumin (g/dL)†	3.8 ± 0.5	3.4 ± 0.5	3.8 ± 0.5	3.7 ± 0.3	3.8 ± 0.5	3.7 ± 0.3	3.8 ± 0.6	3.8 ± 0.4
TG (mg/dL)†	120 ± 58	182 ± 41	123 ± 58	124 ± 62	124 ± 59	122 ± 59	124 ± 43	123 ± 70
LDH (U/L)†	421 ± 165	511 ± 91	407 ± 150	474 ± 187	391 ± 127	483 ± 198*	401 ± 125	448 ± 189
PTC (10 ³ /μL)†	204 ± 86	212 ± 75	192 ± 68	237 ± 115	191 ± 71	227 ± 102	180 ± 68	225 ± 93 *
Neutrophils (10 ³ /μL) †	4.7 ± 3.2	6.1 ± 2.4	4.4 ± 3.1	5.5 ± 3.7	4.5 ± 3.2	5.2 ± 3.3	4.6 ± 3.4	4.8 ± 3.1
Lymphocytes (10 ³ /μL) †	2.9 ± 5.9	3.3 ± 4.6	2.3 ± 4.0	4.5 ± 8.9	2.5 ± 4.3	3.7 ± 7.7	2.6 ± 4.9	3.2 ± 6.5

AHT–Arterial hypertension. HLP–Hyperlipidemia. DM–Diabetes mellitus. HF–Heart failure. FPG–Fasting plasma glucose. TG–Triglycerides. LDH–Lactate dehydrogenase. PTC–Platelet count. Results expressed as † refer to mean ± standard deviation. Results expressed as ‡ refer to number(percentage). * Indicated comparison with patients without in-hospital, 3^o, 6^o or 12^o-month post-discharge non-fatal events ($P < 0.05$).

267

268

269 Patients who suffered from a non-fatal event had higher TBARS levels than controls measured in μmol/L and
 270 expressed as $m \pm SD$. Such differences reached relevance at the following groups: 6^o-month post-discharge non-fatal
 271 events (no: 2.90 ± 1.01 , yes: 3.46 ± 1.15 ; $P = 0.052$). The levels of reduced thiol groups measured in mmol/L and
 272 expressed as $m \pm SD$ were lower in patients who suffered non-fatal events. Such differences reached statistical
 273 significance in the following groups: In-hospital non-fatal event (no: 0.47 ± 0.07 , yes: 0.37 ± 0.05 ; $P = 0.035$). The
 274 results are extended in Fig 1C and 1D.

275

276 Total events

277

278 Patients with any total event had higher TBARS levels than controls measured in μmol/L and expressed as mean (m)
 279 ± SD. These differences reached statistical significance in the following groups: In-hospital (no: 3.01 ± 1.02 , yes:
 280 4.02 ± 1.33 ; $P = 0.030$), 3^o-month (no: 2.84 ± 0.91 , yes: 3.63 ± 1.23 ; $P = 0.006$), 6^o-month (no: 2.7 ± 0.80 , yes: 3.51
 281 ± 1.25 ; $P = 0.007$) and 12^o-month (no: 2.75 ± 0.78 , yes: 3.33 ± 1.19 ; $P = 0.043$) total events. The levels of reduced
 282 thiol groups measured in mmol/L and expressed as $m \pm SD$ were lower in patients who suffered a non-fatal event.
 283 Such differences reached statistical significance in the following groups: In-hospital total events (no: 0.47 ± 0.07 ,

284 yes: 0.37 ± 0.05 ; $P= 0.035$). The results are extended in Fig 1E and 1F.

285

286 Multivariate logistic regression showed a relevant correlation of 12-month total events with TBARS levels, anti-
287 SARS-CoV-2 IgM titers, LDH, PTC and neutrophil and lymphocyte counts. The results of multivariate analysis are
288 shown in Table 3. According to the probability function, a threshold of 0.427 represented a sensitivity and
289 specificity of 80% and 92% for 12-month post-discharge total events. The results related to the ROC curve over the
290 model are shown in Fig 2.

291

292 **Fig 2. Receiver operating characteristics curve model of some laboratory parameters for the 12^o-**
293 **month post-discharge total events**

294 The variables in the model were plasma TBARS, anti-SARS-CoV-2 IgM titers, LDH, PTC, neutrophils
295 count and lymphocytes count. The results are summarized as follows: Area under curve (AUC) 0.870,
296 standard error (SE) 0.047, P-value <0.001, CI95% 0.778 – 0.961. TBARS–Tiobarbituric acid reactive
297 substances. IgM–Inmunoglobulin M. LDH–Lactate dehydrogenase. PTC–Platelet count.

Table 3. Relevant variables in the model of multivariate logistic regression for the 12^o-month post-discharge total events

Variables	Odds ratio (OR)	P-value	CI95%	
			Inferior	Superior
TBARS (umol/L)†	2.918	0.023	1.155	7.367
SARS-CoV-2 IgM (U/L)†	0.978	0.029	0.959	0.998
LDH (U/L)†	1.016	0.017	1.003	1.029
PTC (10 ³ /μL)†	1.019	0.011	1.004	1.034
Neutrophils (10 ³ /μL) †	3.192	0.045	1.024	9.953
Lymphocytes (10 ³ /μL) †	2.345	0.049	1.002	5.486

Omnibus test for coefficients (Chi₂): P-value 0.05. Cox and Snell R-squared: 0.43. Nagelkerke's R-squared: 0.36. Results of the classification table: Sensitivity 0.82, Specificity 0.82. TBARS–Tiobarbituric acid reactive substances. IgM–Inmunoglobulin M. LDH–Lactatum dehydrogenase. PTC–Platelet count

298

299

300 **Time to a negative RT-qPCR for SARS-CoV-2**

301

302 No cutoff point for TBARS or reduced thiols levels showed statistical significance for time to a negative RT-qPCR.

303 Figure 3a-b shows the survival analysis using the mean levels of TBARS and reduced thiols as the cut-off point.

304

305 **Fig 3. Survival analysis by using the Kaplan–Meier estimator**

306 (A) Correlation of plasma levels of reduced thiols with time to a negative RT-qPCR. Log Rank (Mantel-Cox),

307 P-value= 0.544; (B) Correlation of plasma levels of TBARS with time to a negative RT-qPCR. Log Rank

308 (Mantel-Cox), P-value= 0.675. TBARS–Tiobarbituric acid reactive substances. RT-qPCR– Real-time reverse

309 transcriptase-polymerase chain reaction.

310

311 **Time to significant serological titers**

312

313 Considering a cutoff for significant anti-SARS-CoV-2 IgM titers above the mean (40 U/mL), patients with levels of
314 reduced thiols below and above the mean (0.46 mmol/L) showed relevant differences in time to reach significant anti-
315 SARS-CoV-2 IgM titers. No cut-off point for TBARS levels showed relevant results. Figure 4a-b shows the survival
316 analysis using the mean levels of TBARS and reduced thiols as the cut-off point.

317

318 **Fig 4. Survival analysis by using the Kaplan–Meier estimator**

319 (A) Correlation of plasma levels of reduced thiols with time to significant anti-SARS-CoV-2 IgM titers. Log
320 Rank (Mantel-Cox), P-value= 0.033. (B) Correlation of plasma levels of TBARS with time to significant anti-
321 SARS-CoV-2 IgM titers. Log Rank (Mantel-Cox), P-value= 0.227. TBARS–Tiobarbituric acid reactive
322 substances.

323

324 **Discussion**

325

326 The most relevant results are summarized as follows: I) Overall, patients with higher levels of TBARS and lower levels
327 of reduced thiols had more risk of fatal and non-fatal events between hospital admission and the first 12 months post-
328 discharge; II) The presence of any event (fatal or non-fatal) at the end of the first 12 months post-discharge was
329 correlated with some analytical parameters including TBARS levels, anti-SARS-CoV-2 IgM titers, LDH, PTC and
330 WBC counts; III) We have not been able to demonstrate a correlation between differences in TBARS and reduced thiol
331 levels and time to a negative RT-qPCR; IV) However, we found a correlation between differences in plasma reduced
332 thiols and time to achieve significant anti-SARS-CoV-2 IgM titers.

333

334 In a preclinical setting, many lines of evidence support that a combination between overproduction of ROS and a
335 deprived antioxidant system plays a major role in the pathogenesis of SARS-CoV-2 infection. Experimental animal
336 models of severe acute respiratory syndrome (SARS) attempt to elucidate metabolic pathways that may be involved in
337 redox imbalance during SARS-CoV-2 infection while other studies claim the possible role that certain antioxidant
338 molecules use could play during infection [30, 31].

339

340 Metabolic pathways related to oxidative stress could be involved in the severity of SARS-CoV-2 infection in multiple
341 direct and indirect ways. Several studies pointed to the existence of a crosstalk between oxidative stress and
342 inflammation that would involve an interaction between ROS (mainly mitochondrial superoxide and hydroxyl radicals)

343 and some inflammatory mediators due to redox up regulation of some transcription factors such as Nrf2, NF-KB and the
344 NLRP3 inflammasome, as well as their downstream targets, inducing a pro-inflammatory state [32, 33].

345

346 However, non-inflammatory cellular pathways related to redox imbalance and their role in SARS-CoV-2 infection
347 severity and prognostic are not yet fully understood. Indeed, if the role that redox status may play in the prognosis of
348 SARS-CoV-2 infection is poorly understood, the consequences of redox imbalance in the medium and long term are
349 still incalculable although it is possible that mortality and admissions one year ahead could be influenced by an
350 unfavorable redox status during the infection.

351

352 TBARS are a group of molecules related to lipid peroxidation that were implicated in a multitude of acute and chronic
353 diseases [34]. Literature widely supports the role of lipid peroxidation products in the prognosis of some inflammatory
354 diseases and there are some investigation lines trying to discover metabolic pathways related to lipid peroxidation and
355 its role in the severity and evolution of patients with SARS-CoV-2 infection [35, 36]. Reduced thiols are indicators of
356 protein oxidation and have been widely related to pathogenicity and virulence of SARS-CoV-2 infection and, although
357 there are some studies pointing to a prognostic role of reduced thiols in SARS-CoV-2 infection, scientific evidence is
358 still weak [37, 38].

359

360 According to literature, the results related to 12^o-month post-discharge total events could suggest at least three
361 concomitant and interrelated processes in SARS-CoV-2 infection with a prognostic role in the medium and long term as
362 follows: I) Impaired oxidative metabolism, tissue hypoxemia and anaerobic metabolism represented by between-group
363 differences in some oxidative stress markers (TBARS) and LDH; II) endothelial dysfunction, platelet activation and a
364 procoagulant state represented by between-group differences in PTC; and III) inflammation and immune activation
365 represented by between-groups differences in neutrophyl and lymphocyte counts, as well as anti-SARS-CoV-2 IgM
366 titers [39-41].

367

368 In the end, multiple studies have shown the existence of mechanisms related to redox imbalance and a proinflammatory
369 status in SARS-CoV-2 infection. Some of these studies have also investigated the existence of prognostic differences
370 based on certain inflammatory and oxidative stress markers. Several papers have also focused on the implications of
371 RT-qPCR results and serological titers during SARS-CoV2 infection in terms of mechanisms, duration and prognosis of
372 infection. However, to date there is an evidence gap on the implications that redox status during SARS-CoV-2 infection
373 could have in the medium to long term and we do not know how redox status might affect the time required for a

374 negative RT-qPCR or acquisition of significant anti-SARS-CoV-2 IgM titers. Our study aims to be a humble
375 approximation although further evidence is needed.

376

377 **Limitations and strengths**

378

379 This was a prospective single-center study of real clinical practice carried out in elderly Caucasian patients with SARS-
380 CoV-2 infection from the northwest region of Spain (Galicia) who exhibited similar features than elderly people from
381 the western European countries. Our results should be interpreted with caution when applying them to other population,
382 race or ethnicity.

383

384 The sample was not the total population of patients admitted for SARS-CoV-2 in the unit, so the results could be
385 susceptible to a certain sampling error. Although patients were evaluated prospectively, baseline clinical and laboratory
386 data were collected at one point during admission, so some changes in these variables may be relevant and provide
387 more information. Assessing comparability between groups on some variables was complicated because of a low
388 frequency of events of interest in some categories, which could make some results less accurate.

389

390 Regarding the results, we found that younger patients with lower body weight had higher mortality, although it is
391 known that they were patients with a higher degree of cognitive impairment who were probably in a poorer nutritional
392 status. On the other hand, current or former smokers presented a higher number of non-fatal events in some comparison
393 groups. However, in most cases the smoking abuse was stopped more than 10-15 years ago, so a strong implication of
394 that differences on the results would be unlikely.

395

396 In another vein, the frequency of acute treatments (antibiotics, steroids and oxygen therapy use) was higher in patients
397 with worst outcomes. However, these patients usually had a higher frequency of severe disease, so differences in acute
398 management could be more a consequence of severity rather than adverse prognosis.

399

400 **Acknowledgements**

401 We would like to express our gratitude to the patients who participated in the study and their families for their support.

402 We would like to thank the University Hospital and the University of Santiago de Compostela for the support provided.

403

404 **Support**

405 The study was supported by the reference center's library.

406

407 **Financial Disclosure statement**

408 The authors received no specific funding for this work.

409

410 **Supporting information**

411 **S1 Table. General features of comparison groups attending to mortality**

412 **S2 Table. Laboratory findings of comparison groups attending to mortality**

413 **S3 Table. General features of comparison groups attending to non-fatal events**

414 **S4 Table. Laboratory findings of comparison groups attending to non-fatal events**

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439 **References**

440

441 1. Ozma MA, Maroufi P, Khodadadi E, Köse Ş, Esposito I, Ganbarov K, et al. Clinical manifestation, diagnosis,
442 prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. *Infez Med.* 2020;28: 153–165.

443 2. Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
444 and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. *Int J Antimicrob Agents.* 2020;55:
445 105924. doi:10.1016/j.ijantimicag.2020.105924

446 3. Steven S, Frenis K, Oelze M, Kalinovic S, Kuntic M, Bayo Jimenez MT, et al. Vascular Inflammation and Oxidative
447 Stress: Major Triggers for Cardiovascular Disease. *Oxid Med Cell Longev.* 2019;2019: 7092151.
448 doi:10.1155/2019/7092151

449 4. Wenzel P, Kossmann S, Münzel T, Daiber A. Redox regulation of cardiovascular inflammation - Immunomodulatory
450 function of mitochondrial and Nox-derived reactive oxygen and nitrogen species. *Free Radic Biol Med.* 2017;109: 48–
451 60. doi:10.1016/j.freeradbiomed.2017.01.027

452 5. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and
453 prognostic factors based on 4-week follow-up. *J Infect.* 2020;80: 639–645. doi:10.1016/j.jinf.2020.03.019

454 6. Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19: immunity, inflammation and
455 intervention. *Nat Rev Immunol.* 2020;20: 363–374. doi:10.1038/s41577-020-0311-8

456 7. Delgado-Roche L, Mesta F. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus
457 (SARS-CoV) Infection. *Arch Med Res.* 2020;51: 384–387. doi:10.1016/j.arcmed.2020.04.019

458 8. Suhail S, Zajac J, Fossum C, Lowater H, McCracken C, Severson N, et al. Role of Oxidative Stress on SARS-CoV
459 (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. *Protein J.* 2020;39: 644–656. doi:10.1007/s10930-020-
460 09935-8

461 9. Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological
462 samples: Analytical and biological challenges. *Anal Biochem.* 2017;524: 13–30. doi:10.1016/j.ab.2016.10.021

463 10. Turell L, Radi R, Alvarez B. The thiol pool in human plasma: the central contribution of albumin to redox
464 processes. *Free Radic Biol Med.* 2013;65: 244–253. doi:10.1016/j.freeradbiomed.2013.05.050

- 465 11. Kostopoulou E, Kalaitzopoulou E, Papadea P, Skipitari M, Rojas Gil AP, Spiliotis BE, et al. Oxidized lipid-
466 associated protein damage in children and adolescents with type 1 diabetes mellitus: New diagnostic/prognostic clinical
467 markers. *Pediatr Diabetes*. 2021;22: 1135–1142. doi:10.1111/pedi.13271
- 468 12. Mahoney FI, Barthel DW. FUNCTIONAL EVALUATION: THE BARTHEL INDEX. *Md State Med J*. 1965;14:
469 61–65.
- 470 13. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the
471 management of arterial hypertension: The Task Force for the management of arterial hypertension of the European
472 Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial
473 hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens*. 2018;36:
474 1953–2041. doi:10.1097/HJH.0000000000001940
- 475 14. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the
476 management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J*. 2020;41: 111–188.
477 doi:10.1093/eurheartj/ehz455
- 478 15. American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care
479 in Diabetes-2020. *Diabetes Care*. 2020;43: S98–S110. doi:10.2337/dc20-S009
- 480 16. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the
481 diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and
482 chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart
483 Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016;18: 891–975. doi:10.1002/ejhf.592
- 484 17. Wedzicha JA, Miravittles M, Hurst JR, Calverley PMA, Albert RK, Anzueto A, et al. Management of COPD
485 exacerbations: a European Respiratory Society/American Thoracic Society guideline. *Eur Respir J*. 2017;49: 1600791.
486 doi:10.1183/13993003.00791-2016
- 487 18. Navaneethan SD, Zoungas S, Caramori ML, Chan JCN, Heerspink HJL, Hurst C, et al. Diabetes Management in
488 Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. *Ann Intern Med*. 2021;174: 385–
489 394. doi:10.7326/M20-5938
- 490 19. Arias F, Wiggins M, Urman RD, Armstrong R, Pfeifer K, Bader AM, et al. Rapid in-person cognitive screening in
491 the preoperative setting: Test considerations and recommendations from the Society for Perioperative Assessment and
492 Quality Improvement (SPAQI). *J Clin Anesth*. 2020;62: 109724. doi:10.1016/j.jclinane.2020.109724
- 493 20. Arshad AR, Khan I, Shahzad K, Arshad M, Haider SJ, Aslam MJ. Association of Inflammatory Markers with
494 Mortality in COVID-19 Infection. *J Coll Physicians Surg Pak*. 2020;30: 158–163. doi:10.29271/jcpsp.2020.supp2.S158

- 495 21. Payán-Pernía S, Gómez Pérez L, Remacha Sevilla ÁF, Sierra Gil J, Novelli Canales S. Absolute Lymphocytes,
496 Ferritin, C-Reactive Protein, and Lactate Dehydrogenase Predict Early Invasive Ventilation in Patients With COVID-
497 19. *Lab Med.* 2021;52: 141–145. doi:10.1093/labmed/lmaa105
- 498 22. Di Nisio M, Potere N, Candeloro M, Spacone A, Pieramati L, Ferrandu G, et al. Interleukin-6 receptor blockade
499 with subcutaneous tocilizumab improves coagulation activity in patients with COVID-19. *Eur J Intern Med.* 2021;83:
500 34–38. doi:10.1016/j.ejim.2020.10.020
- 501 23. Sule WF, Oluwayelu DO. Real-time RT-PCR for COVID-19 diagnosis: challenges and prospects. *Pan Afr Med J.*
502 2020;35: 121. doi:10.11604/pamj.supp.2020.35.24258
- 503 24. Ong DSY, Fragkou PC, Schweitzer VA, Chemaly RF, Moschopoulos CD, Skevaki C, et al. How to interpret and
504 use COVID-19 serology and immunology tests. *Clin Microbiol Infect.* 2021;27: 981–986.
505 doi:10.1016/j.cmi.2021.05.001
- 506 25. Wasowicz W, Nève J, Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive
507 substances in serum: importance of extraction pH and influence of sample preservation and storage. *Clin Chem.*
508 1993;39: 2522–2526.
- 509 26. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. *Anal*
510 *Biochem.* 1979;95: 351–358. doi:10.1016/0003-2697(79)90738-3
- 511 27. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. *Methods Mol Biol.* 1998;108: 101–
512 106. doi:10.1385/0-89603-472-0:101
- 513 28. Ellman GL. Tissue sulfhydryl groups. *Arch Biochem Biophys.* 1959;82: 70–77. doi:10.1016/0003-9861(59)90090-6
- 514 29. Malone HE, Nicholl H, Coyne I. Fundamentals of estimating sample size. *Nurse Res.* 2016;23: 21–25.
515 doi:10.7748/nr.23.5.21.s5
- 516 30. Freitas FC, Ferreira PHB, Favaro DC, Oliveira RJ de. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-
517 1/CoV-2 Spike Proteins by ACE2-Designed Peptides. *J Chem Inf Model.* 2021;61: 1226–1243.
518 doi:10.1021/acs.jcim.0c01320
- 519 31. De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant
520 therapy of COVID-19. *FASEB J.* 2020;34: 13185–13193. doi:10.1096/fj.202001807
- 521 32. Wang Q-W, Su Y, Sheng J-T, Gu L-M, Zhao Y, Chen X-X, et al. Anti-influenza A virus activity of rhein through
522 regulating oxidative stress, TLR4, Akt, MAPK, and NF-κB signal pathways. *PLoS One.* 2018;13: e0191793.
523 doi:10.1371/journal.pone.0191793
- 524 33. Imai Y, Kuba K, Neely GG, Yaghubian-Malhami R, Perkmann T, van Loo G, et al. Identification of oxidative stress
525 and Toll-like receptor 4 signaling as a key pathway of acute lung injury. *Cell.* 2008;133: 235–249.
526 doi:10.1016/j.cell.2008.02.043

- 527 34. Yilmaz G, Yilmaz FM, Aral Y, Yucel D. Levels of serum sialic acid and thiobarbituric acid reactive substances in
528 subjects with impaired glucose tolerance and type 2 diabetes mellitus. *J Clin Lab Anal.* 2007;21: 260–264.
529 doi:10.1002/jcla.20181
- 530 35. Jacobs W, Lammens M, Kerckhofs A, Voets E, Van San E, Van Coillie S, et al. Fatal lymphocytic cardiac damage
531 in coronavirus disease 2019 (COVID-19): autopsy reveals a ferroptosis signature. *ESC Heart Fail.* 2020.
532 doi:10.1002/ehf2.12958
- 533 36. Coric V, Kosanovic T, Bukumiric Z, Simic T, Pljesa-Ercegovac M, Radojevic AS, et al. Profile of oxidative stress
534 biomarkers in COVID-19: correlation with clinical inflammatory and biochemical parameters. *Free Radical Biology
535 and Medicine.* 2021;177: S132–S133. doi:10.1016/j.freeradbiomed.2021.08.224
- 536 37. Erel Ö, Neşelioğlu S, Ergin Tunçay M, Fırat Oğuz E, Eren F, Akkuş MS, et al. A sensitive indicator for the severity
537 of COVID-19: thiol. *Turk J Med Sci.* 2021;51: 921–928. doi:10.3906/sag-2011-139
- 538 38. Hati S, Bhattacharyya S. Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with
539 Angiotensin-Converting Enzyme 2 Receptor. *ACS Omega.* 2020;5: 16292–16298. doi:10.1021/acsomega.0c02125
- 540 39. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict
541 coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. *Am J Emerg Med.* 2020;38: 1722–
542 1726. doi:10.1016/j.ajem.2020.05.073
- 543 40. Hottz ED, Azevedo-Quintanilha IG, Palhinha L, Teixeira L, Barreto EA, Pão CRR, et al. Platelet activation and
544 platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. *Blood.*
545 2020;136: 1330–1341. doi:10.1182/blood.2020007252
- 546 41. Abeysuriya V, Seneviratne SL, de Silva AP, Mowjood R, Mowjood S, de Silva T, et al. Combination of cycle
547 threshold time, absolute lymphocyte count and neutrophil:lymphocyte ratio is predictive of hypoxia in patients with
548 SARS-CoV-2 infection. *Trans R Soc Trop Med Hyg.* 2021; trab182. doi:10.1093/trstmh/trab182
- 549
550
551
552
553
554
555
556
557
558

559

560

561

562

563

564


565

566


567

568


1a)




1b)



1c)




1d)





medRxiv preprint doi: <https://doi.org/10.1101/2022.05.11.22274952>; this version posted May 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

1e)



1f)






medRxiv preprint doi: <https://doi.org/10.1101/2022.05.11.22274952>; this version posted May 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).


Fig 2

3a)




medRxiv preprint doi: <https://doi.org/10.1101/2022.05.11.22274927>; this version posted May 16, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

3b)



4a)



4b)




Fig 4